PureTech Health PLC (PRTC) News
Filter PRTC News Items
PRTC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRTC News Highlights
- PRTC's 30 day story count now stands at 3.
- Over the past 15 days, the trend for PRTC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PRTC are LYT.
Latest PRTC News From Around the Web
Below are the latest news stories about PURETECH HEALTH PLC that investors may wish to consider to help them evaluate PRTC as an investment opportunity.
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 BillionBOSTON, December 22, 2023--PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion |
PureTech Year End Update and Outlook for 2024BOSTON, December 20, 2023--PureTech Year End Update and Outlook for 2024 |
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023BOSTON, December 07, 2023--PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023 |
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaBOSTON, November 29, 2023--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (Nasdaq: KRTX) ("Karuna") announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of Septemb |
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaBOSTON, November 17, 2023--PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Ph 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia |
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy VolunteersBOSTON, November 14, 2023--PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers |
PureTech to Present at Two Upcoming Investor ConferencesBOSTON, October 17, 2023--PureTech to Present at Two Upcoming Investor Conferences |
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual MeetingBOSTON, October 11, 2023--PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting |
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track DesignationBOSTON, October 04, 2023--PureTech Founded Entity Vedanta Announces First Patient Dosed in Trial of VE202 for Treatment of Ulcerative Colitis & Receives Fast Track Designation |
KarXT, invented at PureTech, submitted for FDA Approval in SchizophreniaBOSTON, September 28, 2023--KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia |